Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

BACKGROUND & AIMS: There are few real-world data on the safety of vedolizumab for treatment of Crohn’s disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious and non-infectious adverse events in clinical practice. METHODS: We...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Gastroenterol Hepatol
Prif Awduron: Meserve, Joseph, Aniwan, Satimai, Koliani-Pace, Jenna L., Shashi, Preeti, Weiss, Aaron, Faleck, David, Winters, Adam, Chablaney, Shreva, Kochhar, Gursimran, Boland, Brigid S., Singh, Siddharth, Hirten, Robert, Shmidt, Eugenia, Hartke, Justin G., Chilukuri, Prianka, Bohm, Matthew, Sagi, Sashidhar Varma, Fischer, Monika, Lukin, Dana, Hudesman, David, Chang, Shannon, Gao, Youran, Sultan, Keith, Swaminath, Arun, Gupta, Nitin, Kane, Sunanda, Loftus, Edward V., Shen, Bo, Sands, Bruce E., Colombel, Jean-Frederic, Siegel, Corey A., Sandborn, William J., Dulai, Parambir S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594363/
https://ncbi.nlm.nih.gov/pubmed/30268561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2018.09.035
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg